592

Tissue Injury and Related Mediators of Pain Exacerbation

Fumimasa Amaya*, Yuta Izumi, Megumi Matsuda and Mika Sasaki

Department of Anesthesiology, Kyoto Prefectural University of Medicine, Kajiicho 465, Kamigyo-Ku, Kyoto 602-8566, Japan

Abstract: Tissue injury and inflammation result in release of various mediators that promote ongoing pain or pain hypersensitivity against mechanical, thermal and chemical stimuli. Pro-nociceptive mediators activate primary afferent neurons directly or indirectly to enhance nociceptive signal transmission to the central nervous system. Excitation of primary afferents by peripherally originating mediators, so-called "peripheral sensitization", is a hallmark of tissue injury-related pain. Many kinds of pro-nociceptive mediators, including ATP, glutamate, kinins, cytokines and tropic factors, synthesized at the damaged tissue, contribute to the development of peripheral sensitization. In the present review we will discuss the molecular mechanisms of peripheral sensitization following tissue injury.

Keywords: Peripheral sensitization, postoperative pain, primary afferent neuron.

INTRODUCTION

Why does tissue injury cause pain? This is an important but difficult question to answer. Although nerve injury as a consequence of tissue damage produces pain, tissue injury does not always cause nerve damage. Tissue inflammation is important when considering the mechanism of pain after tissue damage. We know much about the biology of the neuronal response after tissue inflammation. Most of our knowledge, however, comes from experiments in which tissue was artificially inflamed by the external application of pathogens. Currently, surgical procedures are one of the most common causes of tissue damage. In most cases, surgical procedures are performed under sterile conditions. Most inflammation after surgery is thus aseptic, making it naturally different from infection. However, not much is known about the differences in the reactions of the sensory nervous system to aseptic injury and infection.

Observations on postoperative pain using animal models [1] demonstrated that pain hypersensitivity following tissue injury is strongly associated with activation of primary afferent neurons. The phenomenon of activation of primary afferent neurons by peripherally derived mediators is known as "peripheral sensitization". In the present review, we will introduce peripherally derived pro-nociceptive mediators and discuss how they activate primary afferent neurons at the molecular level.

Mediators Released from Damaged Cells Provoke Pain

Using a co-culture system of primary afferent neurons with keratinocytes, Cook *et al.* demonstrated that nociceptors generate action potentials immediately after the destruction of nearby keratinocytes [2]. This observation indicates that soluble factors released from damaged cells can directly activate neighboring primary afferents, acting in a paracrine fashion. Potassium ions, hydrogen ions, adenosine triphosphate (ATP) and glutamate are candidates for the algogenic factors released from the cytosol (Table 1).

ADENOSINE TRI-PHOSPHATE (ATP)

ATP exists abundantly in the cytoplasm as an energy source. Extracellularly, ATP regulates the activity of various kinds of cells, including nociceptors, via purinergic receptors [3]. P2X (ionotropic) and P2Y (metabotropic) purinergic receptors are present in the primary afferent neurons [4]. Among them, homometric P2X3 and heterometric P2X2/X3 receptors transmit acute nociceptive sensory information. Bath application of ATP produces an inward current in cultured dorsal root ganglion (DRG) neurons under voltagegated conditions [5]. Injection of the P2X receptor agonist, alpha/beta-methyl ATP, induces mechanical allodynia and thermal hyperalgesia at the site of injection [6]. The purinergic receptor antagonist, PPADS, inhibits plantar incision-induced pain hypersensitivity [7]. Metabotropic P2Y1 and P2Y2 receptors are also located in primary afferent neurons [4]. Both P2Y1 and P2Y2 receptors are involved in the enhancement of primary afferent neuron excitability associated with tissue injury [8, 9].

GLUTAMATE

Ionotropic receptors (NMDA, AMPA and kainite receptors) for glutamate are present in primary afferent neurons [10], with the cytosol having a high concentration of glutamate. Glutamate depolarizes cultured DRG neurons [11]. Injection of agonists for NMDA, AMPA and kainite receptors into the glabrous skin produces transient mechanical and thermal hyperalgesia [12]. Hyperalgesia after acute inflammation resulting from formalin application is attenuated by glutamate receptor antagonists [13]. Apart from passive release from damaged tissue, glutamate is actively secreted from primary afferent neurons in response to electrical stimulation or capsaicin treatment [14].

^{*}Address correspondence to this author at the Department of Anesthesiology, Kyoto Prefectural University of Medicine, Kajiicho 465, Kamigyo-Ku, Kyoto 602-8566, Japan; Tel: 81-75-251-5633; Fax: 81-75-251-5843; E-mail: ama@koto.kpu-m.ac.jp

	ATP	Glutamate	Proton
ionotropic receptors	P2X (P2X2, P2X3, P2X4, P2X5, P2X6, P2X7)	AMPA, NMDA, Kainate receptor	ASIC3
metabotropic receptors	P2Y (P2Y1, P2Y2)	Group I-III mGluRs	

Table1. Intracellular Algogenic Factors and their Receptors in the Primary Afferent Neurons

PROTONS AND POTASSIUM

The intracellular environment is slightly more acidic (pH=7.0-7.2) than the extracellular compartment [15]. Acid sensing ion channel (ASIC) 3 is a receptor that senses low pH in the peripheral nervous system. ASIC3 is activated by an acidic environment (pH=7.0) [16]. Genetic knockdown or pharmacological inhibition of ASIC3 reduces incision-induced pain hypersensitivity [17]. ASIC3 is believed to be responsive to chest pain resulting from ischemic cardiac tissue damage [16].

Potassium is one of the major intracellular cations. The difference in potassium concentration between the intra- and extra-cellular fluids determines the voltage potential of cellular membranes. There are several classes of voltage-gated potassium channels in the primary afferent neurons controlling neuronal excitability [18]. Injection of potassium into the dentinal cavity depolarizes the primary afferent fibers [19] and produces ongoing pain.

Nociceptive Molecules as the Initial Step of Inflammation

Bleeding and coagulation due to tissue injury are closely associated with the initiation of inflammation [20]. Intradermal injection of platelets and leukocytes produces axon reflex erythema and acute pain responses in man. Kallikrein released during coagulation produces bradykinin, a strong algogenic factor. Degranulation of activated mast cells results in the release of proteases, cytokines, serotonin and histamine into the extracellular space. These substances sensitize primary afferent neurons to produce pain hypersensitivity [21] (Table **2**).

BRADYKININ

Kinins, including the nonapeptide bradykinin and decapeptide kallidin, are cleaved from kininogen by tissue / plasma kallikrein. Kinins are metabolized rapidly by kininase. Their half-life in plasma is less than 1 min under

normal conditions. Kininase activity is decreased in acidic conditions, which may influence the increased kinin concentration during inflammation. Injection of bradykinin into the hind paw produces severe ongoing pain and hyperalgesia [22]. There are two bradykinin receptors (B1 and B2) in primary afferent neurons [23, 24]. Both of them are G-protein coupled. While the B2 receptor is constantly expressed, the B1 receptor does not exist in naïve primary afferents, but increases after tissue inflammation. B2 receptors play an important role in acute nociception, because their antagonists diminish the nocifensive reaction following formalin, acetic acid, acetylcholine and capsaicin injection. Blocking B2, but not B1 receptors, alleviates plantar incision-induced postoperative pain hypersensitivity [25]. Bradykinin induces protein kinase C (PKC) ε [26] and thereby sensitizes primary afferent neurons by activating TRPV1 [26, 27], TRPA1 [28] and sodium channel Nav1.9 [29].

PROSTAGLANDIN E2

Prostaglandin E2 (PGE2) is one of the major prostanoids derived from arachidonic acid. Two cyclooxygenase enzymes, COX-1 and COX2, mediate biosynthesis of PGE2 [30]. COX-1 is expressed constitutively in various kinds of tissue. COX-2 does not exist in normal tissue but is induced by pro-inflammatory cytokines and growth factors. PGE2 concentration in the skin tissue decreases after the injury that is parallel to the decline of COX-1 expression [31]. By contrast, PGE2 concentration and COX2 expression in the muscle [32] and bone [33] increase after the injury. Four PGE2 receptors (EP1-EP4) have been identified in the primary afferent neurons. All of four receptors are coupled with G-protein but have distinctive intracellular signaling (Table 3). PGE2 increases capsaicin induced currents in cultured rat DRG neurons [34] and sensitize TRPV1 in cultured mouse DRG via activation of PKA and PKCE [35]. Tetrodotoxin (TTX)-resistant sodium current in rat DRG

 Table 2.
 Inflammatory Mediators Affect to the Primary Afferent Neuron

	Bradykinin	Proteinase	PGE2	TNF-α	IL-1β
Receptors	B1*, B2	PAR1**, PAR2 PAR4**	EP1-EP4	TNFR1 TNFR2	IL-1R
Intracellular signaling	РКСє	ΡΚΑ ΡΚCε	РКА РКСє	р38 МАРК РКСғ	P38 MAPK
Biological action	TRPV1↑ TRPA1↑ nav1.9↑	(PAR2) TRPV1↑ TRPV4↑	TRPV1↑ TTX-r VGSC↑	TRPV1↑ TTX-r VGSC↑	TTX-r VGSC↑

*Inducible, does not exist in naive ** anti-nociceptive. VGSC: Voltage-gated sodium

neurons positively regulated by PGE2 [36]. PGE2 induces increase in the magnitude of the peak current and hyperpolarizing shift of current voltage relationship. Gene deletion of two classes of TTX-resistant sodium channels, Nav1.8 [37] or Nav1.9 [29], showed impaired pain hypersensitivity induced by the PGE2 injection.

Table 3. PGE2 Receptors and their Intracellular Signaling

	EP1	EP2	EP3	EP4
G-protein	Gq/11	Gs	Gi	Gs
Intracellular action	ΡΚϹε↑	cAMP↑ PKA↑	cAMP↓ Ca↑	cAMP↑ PKA↑

PROTEINASE-ACTIVATED RECEPTORS (PAR)

Proteinases, such as thrombin, tryptase and trypsin, generated by tissue injury, activate G-protein coupled proteinase activated receptors (PARs) by cleavage of their N-terminal extracellular domain [38]. Among the four members of the PAR family, PAR1, PAR2 and PAR4 are present in primary afferent neurons. PAR2 is activated by trypsin and tryptase. Injection of trypsin into the paw elicits pain hypersensitivity [39]. Activation of PAR2 is associated with thermal hyperalgesia *via* sensitization of TRPV1 [40, 41] and mechanical allodynia *via* TRPV4 activation [42]. PAR2 also activates P2X3 current *via* activation of PKA and PKCε pathway [43].

PAR1 is activated by thrombin. Intra-plantar injection of thrombin increases the nociceptive threshold and diminishes inflammation induced pain hypersensitivity [44]. The antinociceptive effect of PAR1 is involved in opioid signaling, since treatment with PAR1 agonists increases proenkephalin mRNA expression, and its analgesic efficacy is reversed by the opioid receptor antagonist, naloxone [45]. Activation of PAR4 also exerts anti-nociceptive effects against tissue inflammation and visceral hypersensitivity [46, 47].

CYTOKINES

Local treatment with proinflammatory cytokines, including Interleukin (IL)-1ß [48], tumor necrosis factor (TNF)- α [49] and IL-6 [50], induces hyperalgesia at the site of injection. Cytokines directly sensitize primary afferent neurons via their receptors [50-53]. The majority of nociceptors in the DRG have cytokine receptors, including the IL-1 receptor [51], TNF receptor 1 and 2 [52] and IL-6 receptor gp130 [24]. TNF-a activates TRPV1 and TTXresistant sodium channels via a p38 mitogen-activated protein kinase (p38 MAPK) [54, 55] and PKCE [56] dependent mechanism. We recently showed that p38 MAPK is activated in the primary afferent neurons after a plantar incision in a TNF- α dependent manner. IL-1 β increases excitability by sensitizing TTX-resistant slow and persistent sodium channels by activating p38MAPK [51]. In addition to the direct mechanism, IL-1 β leads to the synthesis of prostaglandins [57] and nerve growth factor (NGF) [58], which cause prominent pain hypersensitivity [59].

Nerve Growth Factor (NGF) and Other Tropic Factors

While NGF has been considered to work pro-nociceptive, recent investigations have demonstrated that other tropic factors, including glial cell-derived neurotropic factor (GDNF), brain derived neurotropic factor (BDNF) and insulin-like growth factor (IGF), also have pro-nociceptive effects. They sensitize primary afferent neurons *via* tyrosine kinase-linked receptors.

NERVE GROWTH FACTOR (NGF)

NGF has prominent effects on the sensitization of primary afferent neurons [60]. The receptor for NGF, trk-A, is expressed in the primary afferent neurons. Injection of NGF into the skin causes immediate hyperalgesia [61, 62]. NGF promotes pain hypersensitivity by activating TRPV1 [63], TRPA1 [64], B1 bradykinin receptors [65], TTX-resistant sodium channels and potassium channels [66]. NGF action can be regulated not only by modulating their function, but also by increasing their expression. Tissue inflammation increases TRPV1 positive neurons by NGF-dependent mechanisms [63, 67]. Tissue injury increases NGF synthesis [68] and NGF inhibition alleviates thermal hyperalgesia after incision [69].

Brain-derived Neurotropic Factor (BDNF)

BDNF has a prominent role for the sensitization of the sensory neurons in the spinal cord after the tissue inflammation or nerve injury. Compared to spinal effect, role of BDNF on the peripheral sensitization has been less extensively studied.

The expression of BDNF in the DRG increased after the tissue inflammation [70] or nerve injury [71]. Trk-B, a selective receptor for the BDNF, is expressed in the primary afferent neurons as well. Approximately 10% of primary afferent neurons are positive for trk-B [72] and the expression increased by the tissue inflammation [73]. In cultured neurons, BDNF induces phosphorylation of ERK [73] that subsequently sensitize the primary afferent neurons during the tissue inflammation. Tissue injury induces up-regulation of BDNF and anti-BDNF treatment reduces tissue injury induced pain hypersensitivity [74].

GLIAL CELL-DERIVED NEUROTROPIC FACTOR (GDNF)

GDNF, neurturin, artemin and presepin are members of the GDNF family. Correspondingly, four receptors have been identified: GDNF preferentially binds to GDNF-family co-receptor $\alpha 1$ (GFR $\alpha 1$), neurturin to GFR $\alpha 2$, artemin to GFR $\alpha 3$ and presepin to GFR $\alpha 4$ [75]. GDNF, neurturin and artemin potentiate the function [76] and expression [77] of TRPV1 after inflammation. Injection of GDNF, neurturin and artemin into the hind paw produces hyperalgesia against heat [76]. The concentration of artemin and GDNF increases in injured tissue after paw incision [78].

INSULIN-LIKE GROWTH FACTOR (IGF1)

IGF1 is synthesized in dermal fibroblasts and organizes epidermal growth and differentiation [79]. IGF also promotes proliferation of Schwann cells and facilitates myelination of peripheral nerves [80]. IGF1 synthesis is increased after tissue injury to facilitate wound healing. Receptors for IGF1 (IGFR1) have been identified in the primary afferent neurons. IGF1 activates TRPV1 function in cultured primary afferent neurons [81]. We demonstrated that local injection of IGF1 promotes pain hypersensitivity. Tissue injury increases IGF1 concentration and IGF1 inhibitors alleviate the hyperalgesia after tissue injury [82].

CONCLUSION

In this review, we discussed the mechanisms by which tissue injury drives pain hypersensitivity at the peripheral level. Various mediators, including intracellular algogenic factors, proinflammatory cytokines, kinins and tropic factors, directly activate primary afferent neurons. These factors are also capable of exciting immune cells, increasing their own production and/or that of other classes of mediators. Blocking the action of peripheral mediators at the site of injury could be a promising mechanism-based therapeutic approach to prevent pain hypersensitivity.

It is worthwhile to note that in some conditions, in addition to the peripheral mechanisms, abnormalities in central components, including the spinal cord, brainstem and higher brain structures, are involved in the pathophysiology of pain hypersensitivity after tissue injury.

CONFLICT OF INTEREST

The author(s) confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

- Brennan, T.J.; Vandermeulen, E.P.; Gebhart, G.F. Characterization of a rat model of incisional pain. *Pain*, **1996**, *64*(3), 493-501.
- [2] Cook, S.P.; McCleskey, E.W. Cell damage excites nociceptors through release of cytosolic ATP. *Pain*, 2002, 95(1-2), 41-47.
- [3] Burnstock, G. P2X receptors in sensory neurones. Br. J. Anaesth., 2000, 84(4), 476-488.
- [4] Kobayashi, K.; Yamanaka, H.; Noguchi, K. Expression of ATP receptors in the rat dorsal root ganglion and spinal cord. *Anat. Sci. Int.*, 2013, 88(1), 10-6.
- [5] Ueno, S.; Tsuda, M.; Iwanaga, T.; Inoue, K. Cell type-specific ATP-activated responses in rat dorsal root ganglion neurons. *Br. J. Pharmacol.*, **1999**, *126*(2), 429-436.
- [6] Tsuda, M.; Koizumi, S.; Kita, A.; Shigemoto, Y.; Ueno, S.; Inoue, K. Mechanical allodynia caused by intraplantar injection of P2X receptor agonist in rats: involvement of heteromeric P2X2/3 receptor signaling in capsaicin-insensitive primary afferent neurons. J. Neurosci., 2000, 20(15), RC90.
- [7] Tsuda, M.; Koizumi, S.; Inoue, K. Role of endogenous ATP at the incision area in a rat model of postoperative pain. *Neuroreport*, 2001, 12(8), 1701-1704.
- [8] Moriyama, T.; Iida, T.; Kobayashi, K.; Higashi, T.; Fukuoka, T.; Tsumura, H.; Leon, C.; Suzuki, N.; Inoue, K.; Gachet, C.; Noguchi, K.; Tominaga, M. Possible involvement of P2Y2 metabotropic receptors in ATP-induced transient receptor potential vanilloid receptor 1-mediated thermal hypersensitivity. *J. Neurosci.*, 2003, 23(14), 6058-6062.
- [9] Usachev, Y.M.; DeMarco, S.J.; Campbell, C.; Strehler, E.E.; Thayer, S.A. Bradykinin and ATP accelerate Ca⁽²⁺⁾ efflux from rat sensory neurons *via* protein kinase C and the plasma membrane Ca⁽²⁺⁾ pump isoform 4. *Neuron*, **2002**, *33*(1), 113-122.
- [10] Carlton, S.M.; Hargett, G.L.; Coggeshall, R.E. Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin. *Neurosci. Lett.*, **1995**, *197*(1), 25-28.

- [11] Huettner, J.E. Glutamate receptor channels in rat DRG neurons: activation by kainate and quisqualate and blockade of desensitization by Con A. *Neuron*, 1990, 5(3), 255-266.
- [12] Zhou, S.; Bonasera, L.; Carlton, S.M. Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats. Neuroreport, 1996, 7(4), 895-900.
- [13] Davidson, E.M.; Coggeshall, R.E.; Carlton, S.M. Peripheral NMDA and non-NMDA glutamate receptors contribute to nociceptive behaviors in the rat formalin test. *Neuroreport*, **1997**, *8*(4), 941-946.
- [14] deGroot, J.; Zhou, S.; Carlton, S.M. Peripheral glutamate release in the hindpaw following low and high intensity sciatic stimulation. *Neuroreport*, 2000, 11(3), 497-502.
- [15] Casey, J.R.; Grinstein, S.; Orlowski, J. Sensors and regulators of intracellular pH. Nat. Rev. Mol. Cell Biol., 2010, 11(1), 50-61.
- [16] Sutherland, S.P.; Benson, C.J.; Adelman, J.P.; McCleskey, E.W. Acid-sensing ion channel 3 matches the acid-gated current in cardiac ischemia-sensing neurons. *Proc. Natl. Acad. Sci. U. S. A.*, 2001, 98(2), 711-716.
- [17] Deval, E.; Noel, J.; Gasull, X.; Delaunay, A.; Alloui, A.; Friend, V.; Eschalier, A.; Lazdunski, M.; Lingueglia, E. Acid-sensing ion channels in postoperative pain. J. Neurosci., 2011, 31(16), 6059-6066.
- [18] Pongs, O. Voltage-gated potassium channels: from hyperexcitability to excitement. FEBS Lett., 1999, 452(1-2), 31-35.
- [19] Markowitz, K.; Kim, S. The role of selected cations in the desensitization of intradental nerves. *Proc. Finn. Dent. Soc.*, 1992, 88 Suppl 1, 39-54.
- [20] Robson, M.C.; Steed, D.L.; Franz, M.G. Wound healing: biologic features and approaches to maximize healing trajectories. *Curr. Probl. Surg.*, 2001, 38(2), 72-140.
- [21] Coutaux, A.; Adam, F.; Willer, J.C.; Le Bars, D. Hyperalgesia and allodynia: peripheral mechanisms. *Joint Bone Spine*, 2005, 72(5), 359-371.
- [22] Raja, S.N.; Meyer, R.A.; Campbell, J.N. Peripheral mechanisms of somatic pain. *Anesthesiology*, **1988**, 68(4), 571-590.
- [23] Mizumura, K.; Sugiura, T.; Katanosaka, K.; Banik, R.K.; Kozaki, Y. Excitation and sensitization of nociceptors by bradykinin: what do we know? *Exp. Brain Res.*, 2009, 196(1), 53-65.
- [24] Andratsch, M.; Mair, N.; Constantin, C.E.; Scherbakov, N.; Benetti, C.; Quarta, S.; Vogl, C.; Sailer, C.A.; Uceyler, N.; Brockhaus, J.; Martini, R.; Sommer, C.; Zeilhofer, H.U.; Muller, W.; Kuner, R.; Davis, J.B.; Rose-John, S.; Kress, M. A key role for gp130 expressed on peripheral sensory nerves in pathological pain. J. Neurosci., 2009, 29(43), 13473-13483.
- [25] Muratani, T.; Doi, Y.; Nishimura, W.; Nishizawa, M.; Minami, T.; Ito, S. Preemptive analgesia by zaltoprofen that inhibits bradykinin action and cyclooxygenase in a post-operative pain model. *Neurosci. Res.*, 2005, 51(4), 427-433.
- [26] Cesare, P.; Dekker, L.V.; Sardini, A.; Parker, P.J.; McNaughton, P.A. Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. *Neuron*, **1999**, *23*(3), 617-624.
- [27] Sugiura, T.; Tominaga, M.; Katsuya, H.; Mizumura, K. Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. J. Neurophysiol., 2002, 88(1), 544-548.
- [28] Bandell, M.; Story, G.M.; Hwang, S.W.; Viswanath, V.; Eid, S.R.; Petrus, M.J.; Earley, T.J.; Patapoutian, A. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. *Neuron*, 2004, 41(6), 849-857.
- [29] Amaya, F.; Wang, H.; Costigan, M.; Allchorne, A.J.; Hatcher, J.P.; Egerton, J.; Stean, T.; Morisset, V.; Grose, D.; Gunthorpe, M.J.; Chessell, I.P.; Tate, S.; Green, P.J.; Woolf, C.J. The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J. Neurosci., 2006, 26(50), 12852-12860.
- [30] Dubois, R.N.; Abramson, S.B.; Crofford, L.; Gupta, R.A.; Simon, L.S.; Van De Putte, L.B.; Lipsky, P.E. Cyclooxygenase in biology and disease. *FASEB J*, **1998**, *12*(12), 1063-1073.
- [31] Kampfer, H.; Brautigam, L.; Geisslinger, G.; Pfeilschifter, J.; Frank, S. Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J. Invest. Dermatol., 2003, 120(5), 880-890.
- [32] Shen, W.; Li, Y.; Zhu, J.; Schwendener, R.; Huard, J. Interaction between macrophages, TGF-beta1, and the COX-2 pathway during the inflammatory phase of skeletal muscle healing after injury. *J. Cell Physiol.*, **2008**, *214*(2), 405-412.

- [33] Blackwell, K.A.; Raisz, L.G.; Pilbeam, C.C. Prostaglandins in bone: bad cop, good cop? *Trends Endocrinol. Metab.*, 2010, 21(5), 294-301.
- [34] Pitchford, S.; Levine, J.D. Prostaglandins sensitize nociceptors in cell culture. *Neurosci. Lett.*, 1991, 132(1), 105-108.
- [35] Moriyama, T.; Higashi, T.; Togashi, K.; Iida, T.; Segi, E.; Sugimoto, Y.; Tominaga, T.; Narumiya, S.; Tominaga, M. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. *Mol. Pain*, 2005, 1, 3.
- [36] Gold, M.S.; Reichling, D.B.; Shuster, M.J.; Levine, J.D. Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in nociceptors. *Proc. Natl. Acad. Sci U. S. A.*, **1996**, *93*(3), 1108-1112.
- [37] Villarreal, C.F.; Sachs, D.; Cunha, F.Q.; Parada, C.A.; Ferreira, S.H. The role of Na(V)1.8 sodium channel in the maintenance of chronic inflammatory hypernociception. *Neurosci. Lett.*, 2005, 386(2), 72-77.
- [38] Dery, O.; Corvera, C.U.; Steinhoff, M.; Bunnett, N.W. Proteinaseactivated receptors: novel mechanisms of signaling by serine proteases. *Am. J. Physiol.*, **1998**, 274(6 Pt 1), C1429-1452.
- [39] Vergnolle, N.; Bunnett, N.W.; Sharkey, K.A.; Brussee, V.; Compton, S.J.; Grady, E.F.; Cirino, G.; Gerard, N.; Basbaum, A.I.; Andrade-Gordon, P.; Hollenberg, M.D.; Wallace, J.L. Proteinaseactivated receptor-2 and hyperalgesia: A novel pain pathway. *Nat. Med.*, 2001, 7(7), 821-826.
- [40] Amadesi, S.; Nie, J.; Vergnolle, N.; Cottrell, G.S.; Grady, E.F.; Trevisani, M.; Manni, C.; Geppetti, P.; McRoberts, J.A.; Ennes, H.; Davis, J.B.; Mayer, E.A.; Bunnett, N.W. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. *J. Neurosci.*, 2004, 24(18), 4300-4312.
- [41] Dai, Y.; Moriyama, T.; Higashi, T.; Togashi, K.; Kobayashi, K.; Yamanaka, H.; Tominaga, M.; Noguchi, K. Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinaseinduced inflammatory pain. J. Neurosci., 2004, 24(18), 4293-4299.
- [42] Grant, A.D.; Cottrell, G.S.; Amadesi, S.; Trevisani, M.; Nicoletti, P.; Materazzi, S.; Altier, C.; Cenac, N.; Zamponi, G.W.; Bautista-Cruz, F.; Lopez, C.B.; Joseph, E.K.; Levine, J.D.; Liedtke, W.; Vanner, S.; Vergnolle, N.; Geppetti, P.; Bunnett, N.W. Proteaseactivated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. *J. Physiol.*, **2007**, 578(Pt 3), 715-733.
- [43] Wang, S.; Dai, Y.; Kobayashi, K.; Zhu, W.; Kogure, Y.; Yamanaka, H.; Wan, Y.; Zhang, W.; Noguchi, K. Potentiation of the P2X3 ATP receptor by PAR-2 in rat dorsal root ganglia neurons, through protein kinase-dependent mechanisms, contributes to inflammatory pain. *Eur. J. Neurosci.*, **2012**, *36*(3), 2293-2301.
- [44] Asfaha, S.; Brussee, V.; Chapman, K.; Zochodne, D.W.; Vergnolle, N. Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli. *Br. J. Pharmacol.*, 2002, 135(5), 1101-1106.
- [45] Martin, L.; Auge, C.; Boue, J.; Buresi, M.C.; Chapman, K.; Asfaha, S.; Andrade-Gordon, P.; Steinhoff, M.; Cenac, N.; Dietrich, G.; Vergnolle, N. Thrombin receptor: An endogenous inhibitor of inflammatory pain, activating opioid pathways. *Pain*, **2009**, *146*(1-2), 121-129.
- [46] Asfaha, S.; Cenac, N.; Houle, S.; Altier, C.; Papez, M.D.; Nguyen, C.; Steinhoff, M.; Chapman, K.; Zamponi, G.W.; Vergnolle, N. Protease-activated receptor-4: a novel mechanism of inflammatory pain modulation. *Br. J. Pharmacol.*, **2007**, *150*(2), 176-185.
- [47] Auge, C.; Balz-Hara, D.; Steinhoff, M.; Vergnolle, N.; Cenac, N. Protease-activated receptor-4 (PAR 4): a role as inhibitor of visceral pain and hypersensitivity. *Neurogastroenterol. Motil.*, 2009, 21(11), 1189-e1107.
- [48] Fukuoka, H.; Kawatani, M.; Hisamitsu, T.; Takeshige, C. Cutaneous hyperalgesia induced by peripheral injection of interleukin-1 beta in the rat. *Brain Res*, **1994**, 657(1-2), 133-140.
- [49] Junger, H.; Sorkin, L.S. Nociceptive and inflammatory effects of subcutaneous TNFalpha. *Pain*, 2000, 85(1-2), 145-151.
- [50] Obreja, O.; Schmelz, M.; Poole, S.; Kress, M. Interleukin-6 in combination with its soluble IL-6 receptor sensitises rat skin nociceptors to heat, *in vivo. Pain*, **2002**, *96*(1-2), 57-62.
- [51] Binshtok, A.M.; Wang, H.; Zimmermann, K.; Amaya, F.; Vardeh, D.; Shi, L.; Brenner, G.J.; Ji, R.R.; Bean, B.P.; Woolf, C.J.; Samad,

T.A. Nociceptors are interleukin-1beta sensors. J. Neurosci., 2008, 28(52), 14062-14073.

- [52] Li, Y.; Ji, A.; Weihe, E.; Schafer, M.K. Cell-specific expression and lipopolysaccharide-induced regulation of tumor necrosis factor alpha (TNFalpha) and TNF receptors in rat dorsal root ganglion. J. *Neurosci.*, 2004, 24(43), 9623-9631.
- [53] Schafers, M.; Lee, D.H.; Brors, D.; Yaksh, T.L.; Sorkin, L.S. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J. Neurosci., 2003, 23(7), 3028-3038.
- [54] Jin, X.; Gereau, R.W.t. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J. Neurosci., 2006, 26(1), 246-255.
- [55] Nicol, G.D.; Lopshire, J.C.; Pafford, C.M. Tumor necrosis factor enhances the capsaicin sensitivity of rat sensory neurons. J. *Neurosci.*, **1997**, *17*(3), 975-982.
- [56] Constantin, C.E.; Mair, N.; Sailer, C.A.; Andratsch, M.; Xu, Z.Z.; Blumer, M.J.; Scherbakov, N.; Davis, J.B.; Bluethmann, H.; Ji, R.R.; Kress, M. Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. *J. Neurosci.*, **2008**, 28(19), 5072-5081.
- [57] Maier, J.A.; Hla, T.; Maciag, T. Cyclooxygenase is an immediateearly gene induced by interleukin-1 in human endothelial cells. J Biol. Chem., 1990, 265(19), 10805-10808.
- [58] Safieh-Garabedian, B.; Poole, S.; Allchorne, A.; Winter, J.; Woolf, C.J. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. *Br. J. Pharmacol.*, **1995**, *115*(7), 1265-1275.
- [59] Cunha, T.M.; Verri, W.A., Jr.; Silva, J.S.; Poole, S.; Cunha, F.Q.; Ferreira, S.H. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. *Proc. Natl. Acad. Sci. U. S. A.*, 2005, *102*(5), 1755-1760.
- [60] Jankowski, M.P.; Koerber, H.R. Neurotrophic Factors and Nociceptor Sensitization. FL: CRC Press; **2010**. Chapter 2
- [61] Andreev, N.; Dimitrieva, N.; Koltzenburg, M.; McMahon, S.B. Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. *Pain*, **1995**, *63*(1), 109-115.
- [62] Dyck, P.J.; Peroutka, S.; Rask, C.; Burton, E.; Baker, M.K.; Lehman, K.A.; Gillen, D.A.; Hokanson, J.L.; O'Brien, P.C. Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. *Neurology*, **1997**, *48*(2), 501-505.
- [63] Ji, R.R.; Samad, T.A.; Jin, S.X.; Schmoll, R.; Woolf, C.J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. *Neuron*, **2002**, *36*(1), 57-68.
- [64] Malin, S.; Molliver, D.; Christianson, J.A.; Schwartz, E.S.; Cornuet, P.; Albers, K.M.; Davis, B.M. TRPV1 and TRPA1 function and modulation are target tissue dependent. *J. Neurosci.*, 2011, 31(29), 10516-10528.
- [65] Rueff, A.; Dawson, A.J.; Mendell, L.M. Characteristics of nerve growth factor induced hyperalgesia in adult rats: dependence on enhanced bradykinin-1 receptor activity but not neurokinin-1 receptor activation. *Pain*, **1996**, 66(2-3), 359-372.
- [66] Zhang, Y.H.; Vasko, M.R.; Nicol, G.D. Ceramide, a putative second messenger for nerve growth factor, modulates the TTXresistant Na(+) current and delayed rectifier K(+) current in rat sensory neurons. J. Physiol., 2002, 544(Pt 2), 385-402.
- [67] Amaya, F.; Oh-hashi, K.; Naruse, Y.; Iijima, N.; Ueda, M.; Shimosato, G.; Tominaga, M.; Tanaka, Y.; Tanaka, M. Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons. *Brain Res.*, **2003**, *963*(1-2), 190-196.
- [68] Wu, C.; Boustany, L.; Liang, H.; Brennan, T.J. Nerve growth factor expression after plantar incision in the rat. *Anesthesiology*, 2007, 107(1), 128-135.
- [69] Banik, R.K.; Subieta, A.R.; Wu, C.; Brennan, T.J. Increased nerve growth factor after rat plantar incision contributes to guarding behavior and heat hyperalgesia. *Pain*, 2005, *117*(1-2), 68-76.
- [70] Mannion, R.J.; Costigan, M.; Decosterd, I.; Amaya, F.; Ma, Q.P.; Holstege, J.C.; Ji, R.R.; Acheson, A.; Lindsay, R.M.; Wilkinson, G.A.; Woolf, C.J. Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain

hypersensitivity. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(16), 9385-9390.

- [71] Fukuoka, T.; Yamanaka, H.; Kobayashi, K.; Okubo, M.; Miyoshi, K.; Dai, Y.; Noguchi, K. Re-evaluation of the phenotypic changes in L4 dorsal root ganglion neurons after L5 spinal nerve ligation. *Pain*, 2012, 153(1), 68-79.
- [72] Kashiba, H.; Uchida, Y.; Senba, E. Distribution and colocalization of NGF and GDNF family ligand receptor mRNAs in dorsal root and nodose ganglion neurons of adult rats. *Brain Res. Mol. Brain Res.*, 2003, 110(1), 52-62.
- [73] Lin, Y.T.; Ro, L.S.; Wang, H.L.; Chen, J.C. Up-regulation of dorsal root ganglia BDNF and trkB receptor in inflammatory pain: an *in vivo* and *in vitro* study. J. Neuroinflamm., 2011, 8, 126.
- [74] Li, C.Q.; Xu, J.M.; Liu, D.; Zhang, J.Y.; Dai, R.P. Brain derived neurotrophic factor (BDNF) contributes to the pain hypersensitivity following surgical incision in the rats. *Mol. Pain*, **2008**, *4*, 27.
- [75] Bespalov, M.M.; Saarma, M. GDNF family receptor complexes are emerging drug targets. *Trends Pharmacol. Sci.*, 2007, 28(2), 68-74.
- [76] Malin, S.A.; Molliver, D.C.; Koerber, H.R.; Cornuet, P.; Frye, R.; Albers, K.M.; Davis, B.M. Glial cell line-derived neurotrophic factor family members sensitize nociceptors *in vitro* and produce thermal hyperalgesia *in vivo*. J. Neurosci., 2006, 26(33), 8588-8599.

Received: January 28, 2013

- [77] Amaya, F.; Shimosato, G.; Nagano, M.; Ueda, M.; Hashimoto, S.; Tanaka, Y.; Suzuki, H.; Tanaka, M. NGF and GDNF differentially regulate TRPV1 expression that contributes to development of inflammatory thermal hyperalgesia. *Eur. J. Neurosci.*, **2004**, *20*(9), 2303-2310.
- [78] Spofford, C.M.; Brennan, T.J. Gene expression in skin, muscle, and dorsal root ganglion after plantar incision in the rat. *Anesthesiology*, 2012, 117(1), 161-172.
- [79] Edmondson, S.R.; Thumiger, S.P.; Werther, G.A.; Wraight, C.J. Epidermal homeostasis: the role of the growth hormone and insulin-like growth factor systems. *Endocr. Rev.*, 2003, 24(6), 737-764.
- [80] Kimpinski, K.; Mearow, K. Neurite growth promotion by nerve growth factor and insulin-like growth factor-1 in cultured adult sensory neurons: role of phosphoinositide 3-kinase and mitogen activated protein kinase. J. Neurosci. Res., 2001, 63(6), 486-499.
- [81] Van Buren, J.J.; Bhat, S.; Rotello, R.; Pauza, M.E.; Premkumar, L.S. Sensitization and translocation of TRPV1 by insulin and IGF-I. *Mol. Pain*, 2005, *1*, 17.
- [82] Miura, M.; Sasaki, M.; Mizukoshi, K.; Shibasaki, M.; Izumi, Y.; Shimosato, G.; Amaya, F. Peripheral sensitization caused by insulin-like growth factor 1 contributes to pain hypersensitivity after tissue injury. *Pain*, **2011**, *152*(4), 888-895.

Revised: June 13, 2013

Accepted: July 12, 2013